Glenmark Generics receives USFDA nod for Lamotrigine tablets

07 May 2012 Evaluate

Glenmark Generics Inc USA, a subsidiary of Glenmark Generics, has been granted final approval for their abbreviated new drug application (ANDA) by the United States Food and Drug Administration (USFDA) for Lamotrigine 25, 100, 150 and 200mg Tables, their generic version of Lamictal by GlaxoSmithKline.

Lamotrigine is an antiepileptic drug indicated for Epilepsy and Bipolar Disorder. The sales for the 12 month period ending December 2011, Lamotrigine Tablets garnered $62 million.

With this, the company's current portfolio consists of 80 generic products authorized for distribution in the US market and 38 ANDA's filed with the USFDA pending approval.

Glenmark Generics is a subsidiary of Glenmark Pharmaceuticals (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries.

Glenmark Pharma Share Price

1626.55 -15.00 (-0.91%)
08-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1837.30
Dr. Reddys Lab 1370.60
Cipla 1495.05
Lupin 2252.40
Zydus Lifesciences 981.55
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.